Entresto (sacubitril/valsartan) has become a cornerstone in the management of heart failure, yet many patients and caregivers wonder at what stage of heart failure is entresto prescribed. Because of that, understanding the appropriate stage requires a look at current clinical guidelines, the progression of heart failure, and how this medication fits into guideline-directed medical therapy. Unlike older therapies that were introduced only after symptoms worsened, Entresto is now recommended earlier in the disease course for eligible patients, reflecting a shift toward proactive, evidence-based intervention.
The ACC/AHA Heart Failure Staging System
Heart failure is classified using the American College of Cardiology (ACC) and American Heart Association (AHA) staging system, which categorizes patients from Stage A through Stage D based on risk factors and structural heart disease. Stage A identifies patients at high risk but without structural heart disease or symptoms. Stage B involves structural heart disease (such as left ventricular hypertrophy or reduced ejection fraction) without prior symptoms of heart failure. Stage C includes patients with structural heart disease who have experienced or are experiencing symptomatic heart failure. Stage D represents refractory heart failure requiring specialized interventions, including advanced therapies like ventricular assist devices or transplantation.
The staging framework helps clinicians tailor therapies to the patient's current physiological state. Entresto's role spans multiple stages, but its prescription is most strongly associated with specific clinical parameters that define modern heart failure management Small thing, real impact..
What Entresto Is and How It Works
Entresto is a fixed-dose combination of sac
ubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB). By inhibiting neprilysin, sacubitril prevents the breakdown of natriuretic peptides, which promote vasodilation, natriuresis, and anti-remodeling effects. Concurrently, valsartan blocks angiotensin II receptors, mitigating vasoconstriction, sodium retention, and myocardial fibrosis. This unique dual mechanism—termed angiotensin receptor-neprilysin inhibition (ARNI)—simultaneously blocks the harmful effects of the renin-angiotensin-aldosterone system (RAAS) while enhancing the beneficial natriuretic peptide system. This synergistic action addresses the neurohormonal dysregulation central to heart failure progression more comprehensively than RAAS inhibition alone.
Guideline-Directed Indications: Focus on Ejection Fraction
Current ACC/AHA/HFSA guidelines position Entresto as a foundational therapy (Class 1 recommendation) for patients with Stage C Heart Failure with Reduced Ejection Fraction (HFrEF; LVEF ≤ 40%) who remain symptomatic (NYHA Class II–III) despite optimal background therapy, or as a replacement for an ACE inhibitor (ACEi) or ARB in treatment-naïve patients. The landmark PARADIGM-HF trial demonstrated superior reductions in cardiovascular death and heart failure hospitalization compared to enalapril, establishing this indication Worth keeping that in mind..
More recently, the indication has expanded based on the PARAGON-HF and PARALLAX trials. Entresto now holds a Class 2a recommendation for Heart Failure with Mildly Reduced Ejection Fraction (HFmrEF; LVEF 41–49%) and a Class 2b recommendation for select patients with Heart Failure with Preserved Ejection Fraction (HFpEF; LVEF ≥ 50%), particularly those at the lower end of the EF spectrum or with evidence of elevated natriuretic peptides. This broadened scope reflects the recognition that the neurohormonal benefits of ARNI therapy extend beyond severe systolic dysfunction.
Transitioning from ACE Inhibitors or ARBs
A critical practical consideration is the mandatory 36-hour washout period when switching from an ACE inhibitor to Entresto. This interval minimizes the risk of angioedema, a rare but serious adverse event resulting from the accumulation of bradykinin and substance P when both neprilysin and ACE are inhibited simultaneously. No washout is required when switching from an ARB or other antihypertensives. Clinicians must also ensure the patient is hemodynamically stable (systolic blood pressure ≥ 100 mmHg), euvolemic, and has an estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m² (or ≥ 15 mL/min/1.73m² for the lower starting dose) before initiation Simple, but easy to overlook..
Monitoring and Special Populations
After initiation, patients require close monitoring of blood pressure, renal function (creatinine/eGFR), and potassium levels within 1–2 weeks, then periodically. Dose titration to the target dose (sacubitril/valsartan 97/103 mg twice daily) should be pursued as tolerated, though clinical benefit is observed even at lower doses. Entresto is contraindicated in pregnancy (Category D) due to fetal toxicity and in patients with a history of angioedema related to ACEi, ARB, or ARNI therapy. Caution is advised in patients with significant hepatic impairment.
Conclusion
Entresto is prescribed primarily at Stage C of the ACC/AHA classification—when structural heart disease has manifested as symptomatic heart failure—with its strongest evidence base in HFrEF and expanding utility in HFmrEF and HFpEF. It represents a paradigm shift from sequential add-on therapy to early, potent neurohormonal modulation. By replacing ACE inhibitors or ARBs as the preferred RAAS blockade strategy in eligible patients, Entresto offers a proven mortality and morbidity benefit that alters the natural history of the disease. For clinicians and patients alike, recognizing the appropriate stage for initiation—early in the symptomatic phase, before irreversible decompensation occurs—is key to maximizing the lifespan and quality of life benefits this landmark therapy provides It's one of those things that adds up..
